Cargando…
Lysosomotropic agents as HCV entry inhibitors
HCV has two envelop proteins named as E1 and E2 which play an important role in cell entry through two main pathways: direct fusion at the plasma membrane and receptor-mediated endocytosis. Fusion of the HCV envelope proteins is triggered by low pH within the endosome. Lysosomotropic agents (LA) suc...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090357/ https://www.ncbi.nlm.nih.gov/pubmed/21481279 http://dx.doi.org/10.1186/1743-422X-8-163 |
_version_ | 1782203143977697280 |
---|---|
author | Ashfaq, Usman A Javed, Tariq Rehman, Sidra Nawaz, Zafar Riazuddin, Sheikh |
author_facet | Ashfaq, Usman A Javed, Tariq Rehman, Sidra Nawaz, Zafar Riazuddin, Sheikh |
author_sort | Ashfaq, Usman A |
collection | PubMed |
description | HCV has two envelop proteins named as E1 and E2 which play an important role in cell entry through two main pathways: direct fusion at the plasma membrane and receptor-mediated endocytosis. Fusion of the HCV envelope proteins is triggered by low pH within the endosome. Lysosomotropic agents (LA) such as Chloroquine and Ammonium chloride (NH(4)Cl) are the weak bases and penetrate in lysosome as protonated form and increase the intracellular pH. To investigate the antiviral effect of LA (Chloroquine and NH(4)Cl) on pH dependent endocytosis, HCV pseudoparticles (HCVpp) of 1a and 3a genotype were produced and used to infect liver cells. The toxicological effects of Chloroquine and NH(4)Cl were tested in liver cells through MTT cell proliferation assay. For antiviral screening of Chloroquine and NH(4)Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer. The results demonstrated that Chloroquine and NH(4)Cl showed more than 50% reduction of virus infectivity at 50 μM and 10 mM concentrations respectively. These results suggest that inhibition of HCV at fusion step by increasing the lysosomal pH will be better option to treat chronic HCV. |
format | Text |
id | pubmed-3090357 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-30903572011-05-10 Lysosomotropic agents as HCV entry inhibitors Ashfaq, Usman A Javed, Tariq Rehman, Sidra Nawaz, Zafar Riazuddin, Sheikh Virol J Research HCV has two envelop proteins named as E1 and E2 which play an important role in cell entry through two main pathways: direct fusion at the plasma membrane and receptor-mediated endocytosis. Fusion of the HCV envelope proteins is triggered by low pH within the endosome. Lysosomotropic agents (LA) such as Chloroquine and Ammonium chloride (NH(4)Cl) are the weak bases and penetrate in lysosome as protonated form and increase the intracellular pH. To investigate the antiviral effect of LA (Chloroquine and NH(4)Cl) on pH dependent endocytosis, HCV pseudoparticles (HCVpp) of 1a and 3a genotype were produced and used to infect liver cells. The toxicological effects of Chloroquine and NH(4)Cl were tested in liver cells through MTT cell proliferation assay. For antiviral screening of Chloroquine and NH(4)Cl, liver cells were infected with HCVpp of 3a and 1a genotype in the presence or absence of different concentrations of Chloroquine and NH4Cl and there luciferase activity was determined by using a luminometer. The results demonstrated that Chloroquine and NH(4)Cl showed more than 50% reduction of virus infectivity at 50 μM and 10 mM concentrations respectively. These results suggest that inhibition of HCV at fusion step by increasing the lysosomal pH will be better option to treat chronic HCV. BioMed Central 2011-04-12 /pmc/articles/PMC3090357/ /pubmed/21481279 http://dx.doi.org/10.1186/1743-422X-8-163 Text en Copyright ©2011 Ashfaq et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Ashfaq, Usman A Javed, Tariq Rehman, Sidra Nawaz, Zafar Riazuddin, Sheikh Lysosomotropic agents as HCV entry inhibitors |
title | Lysosomotropic agents as HCV entry inhibitors |
title_full | Lysosomotropic agents as HCV entry inhibitors |
title_fullStr | Lysosomotropic agents as HCV entry inhibitors |
title_full_unstemmed | Lysosomotropic agents as HCV entry inhibitors |
title_short | Lysosomotropic agents as HCV entry inhibitors |
title_sort | lysosomotropic agents as hcv entry inhibitors |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3090357/ https://www.ncbi.nlm.nih.gov/pubmed/21481279 http://dx.doi.org/10.1186/1743-422X-8-163 |
work_keys_str_mv | AT ashfaqusmana lysosomotropicagentsashcventryinhibitors AT javedtariq lysosomotropicagentsashcventryinhibitors AT rehmansidra lysosomotropicagentsashcventryinhibitors AT nawazzafar lysosomotropicagentsashcventryinhibitors AT riazuddinsheikh lysosomotropicagentsashcventryinhibitors |